Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.410
-0.050 (-3.42%)
At close: Aug 28, 2026, 4:00 PM EDT
1.390
-0.020 (-1.42%)
After-hours: Aug 28, 2026, 7:49 PM EDT

Coherus Oncology Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Coherus Oncology stock has a consensus rating of "Buy" and an average price target of $7.75. The average 1-year stock price forecast is 449.65% higher than the current stock price, while the lowest is $4.00 (+183.69%) and the highest is $10 (+609.22%).

Price Target: $7.75 (+449.65%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$7.75$8.50$10
Change+183.69%+449.65%+502.84%+609.22%

Analyst Ratings

The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Aug '26
Strong Buy444554
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total666776

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Buy
Maintains
$4
BuyMaintains$4+183.69%Aug 7, 2026
Guggenheim
Guggenheim
Buy
Maintains
$12$10
BuyMaintains$12$10+609.22%Aug 7, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$10
BuyMaintains$10+609.22%Aug 6, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$7
BuyReiterates$7+396.45%Aug 6, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 28, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
60.81M
from 42.17M
Increased by 44.19%
Revenue Next Year
100.37M
from 60.81M
Increased by 65.06%
EPS This Year
-0.86
from -1.36
EPS Next Year
-0.63
from -0.86
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
326.55M211.04M257.24M26.39M42.17M60.81M
Revenue Growth
-31.37%-35.37%21.89%-89.74%59.81%44.19%
Gross Profit
268.96M140.96M98.25M17.66M28.36M45.60M
Gross Margin
82.36%66.79%38.19%66.93%67.24%75.00%
Operating Income
-263.86M-256.88M-193.20M-189.05M-176.43M-136.35M
Net Income
-287.10M-291.75M-237.89M28.51M168.02M-139.00M
EPS
-----1.36-0.86
Free Cash Flow
-60.97M-186.86M-69.86M-13.17M-68.72M-81.00M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High65.8M
Avg60.8M
Low58.6M

Revenue Growth

Revenue Growth202620272028
High
55.9%
Avg
44.2%
Low
39.0%

EPS Forecast

EPS202620272028
High-0.84
Avg-0.86
Low-0.87

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-